Hoba Therapeutics is Danish biotech developing restorative treatments for pain, hearing loss, and sensory neuron disorders. HB-086 is under development for the treatment of pain in multiple chronic neuropathic pain indications. HB-086 is a non-opioid compound with a unique MoA targeting the peripheral nervous system to reverse neuropathic pain and thus targeting the underlying cause of the disease. HB-097 is a restorative treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage.
Attgeno develops novel nitric oxide donators which are selective for the pulmonary circulation, making them safe and without systemic side-effects.Attgeno has developed Supernitro, a first in class therapy for the specific delivery of Nitric Oxide (NO) in the lung for prevention and treatment of pulmonary hypertension. By the donation of NO in the lungs, Supernitro replaces the decrease in NO production that is a well-known consequence of different diseases leading to increased risk for pulmonary hypertension, a condition associated with severe morbidity and mortality.
Eir ventures has established itself as a well-respected professional investor in the Nordic life science ecosystem and will continue to build the organization and network to key stakeholders in the region. In accordance with this aim, Eir Ventures is expanding the team with three new partners. The three new Partners will join the Founding Partners Magnus Persson MD PhD, Stephan Christgau PhD and Amanda Hayward PhD. Concomitant with this expansion of the investment team, Mr Andreas Segerros will be leaving the firm to pursue an alternate professional role.
Cinclus Pharma is a Swedish biopharmaceutical company that is developing novel small molecules for the treatment of gastroesophageal reflux disease (GERD). The lead candidate, linaprazan glurate, belongs to a novel class of drugs, so called Potassium-Competitive Acid Blockers (P-CABs), that result in faster regulation of intragastric pH by a different mechanism of action compared to PPIs. The drug is in Phase 2 development in Europe and the US and has the potential to heal esophageal injuries and alleviate GERD symptoms more effectively than current pharmaceutical therapies including PPIs.
Eir Ventures today announced the completion of an investment in Strike Pharma, a Swedish biotechnology company that is developing personalized precision medicines within the immune-oncology space. The technology offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.
University of Copenhagen and Eir Ventures has agreed a unique co-investment agreement where the University allocates DKK 15 million to co-investments with Eir Ventures.
Pok Yeung Lee and Jorge Pérez Hermilla, two MMSc students from the Bioentrepreneurship program anchored at Karolinska Institutet and Royal Institute of Technology, will join the Eir Ventures Stockholm team in January 2022.
Pok Yeung has previous investment analyst and business consultant experience and has most recently been working with life science investments at Hadean Ventures in Stockholm. He has a BSc in Biotechnology and Business from Hong Kong University of Science and Technology. Jorge has previous strategy consulting experience and has most recently been working with life science equity investments at Öhman Fonder. He has a MD from University of Santiago de Compostela in Spain.
Eir Ventures welcomes Tobias Horneman-Thielcke as senior Principal in the Eir Ventures Team. Tobias is a physician and holds a BA in Law. Tobias started his career working as a physician in the clinic and later transferred to the pharmaceutical industry, where he spent several years in various regional and global leadership positions for Sanofi Genzyme and Y-mAbs. Tobias is experienced within rare diseases, immunology and oncology, developing and managing strategy, product launches and drug positioning with R&D. Tobias is also the founder of a medtech startup company, Connect2Treat.com, that digitalises HCP and pharma interactions. The position is in Copenhagen
Eir Ventures Partners AB (“Eir Ventures” or “the Fund”), a Nordic Life Science Venture Capital manager, today announced the final close of its fund Eir Ventures I AB of EUR 122.3 million.
Eir Ventures today announced the completion of an investment in ArgusEye, a biotechnology company developing sensor solutions for real-time detection of biological systems and processes.